Global Market Research Reports : Ken Research: Latin America Cancer Screening Market

Wednesday, October 16, 2019

Rise in Prevalence of Target Disorders Expected to Drive Latin America Cancer Screening Market over the Forecast Period: Ken Research

Cancer screening aims to distinguish cancer before symptoms appear. It involves blood tests, DNA tests, urine tests, medical imaging tests and other tests. The benefits of screening in terms of cancer inhibition, early detection and subsequent treatment must be considered against any harms.

According to study, “Latin America Cancer Screening Market (2018-2023)” the key companies operating in the Latin America cancer screening market are Abbott diagnostics, GE Healthcare, Roche Diagnostics, Becton, Dickinson and Company, Hologic Inc., Roche Molecular Inc., Celera Group, Auto Genomics Inc., ELI Tech Group, Quest Inc., Applied Biosystems Inc., Trans Genomic Inc., BioRad Laboratores Inc., PerkinELmer Inc. The key players are scheduling for investing the attractive amount of money for advancing the technologies and increasing the awareness related to this while the government of an economy is also taking initiative in this regards and creating the profitable strategies & policies which further proved to be profited for both the consumer and players.

Based on type of cancer, cancer screening market is segmented into breast cancer, bowel cancer, cervical cancer, lung cancer, prostate cancer, colorectal cancer, oral cancer, skin cancer, pancreatic cancer and other cancers. Breast cancer involves clinical breast examination, mammography, Magnetic resonance imaging (MRI), and breast self-examination tests. Cervical cancer involves Pap test and Human papillomavirus (HPV) testing. Lung cancer involves Low-dose helical or spiral computed tomography (CT or CAT) scan. Prostate cancer involves Prostate-specific antigen (PSA) test and Digital rectal examination (DRE). Colorectal cancer involves fecal occult blood test (FOBT), stool DNA tests, colonoscopy test, double contrast barium enema and sigmoidoscopy test. Additionally, skin cancer involves dermoscopy, skin self-examination and complete skin exam test. Based on product type, market is segmented into reagents & kits, services, instruments and data management system. Based on screening type, market is bifurcated into the market is segmented into laboratory tests, imaging tests, biopsy tests, genetic tests and endoscopy tests. Imaging test make pictures or images of areas inside the body while genetic test looks for certain gene mutations or changes that are linked to types of cancer. In addition, based on end-users, market is segmented into independent physicians & clinics, hospitals and laboratories.

The cancer screening market is driven by rise in prevalence of target disorders, followed by increase in aging population, rise in support from government in the form of awareness campaigns & performance-based reimbursements, increase in awareness among people, and presence of favorable government initiatives for early disease diagnosis. However, high screening test costs, imbalance in socio-economic & political scenario and inadequate healthcare access in developing countries may impact the market.

Based on geography, cancer screening market is segmented into Colombia, Brazil, and the rest of Latin America. It is anticipated that market will be reached at fast pace owing to rise in technological advancements and increase in incidence of chronic diseases over the forecast period. It is expected that the market will be reached at US $ 30.06 billion, by 2023, at a CAGR of 7.19%. It is projected that the cancer screening market of will increase across the Latin America region more positively over the coming years.

For more information, click on the link below:

Latin America Cancer Screening Market

Contact Us:

Ken Research

Ankur Gupta, Head Marketing & Communications

sales@kenresearch.com

+91 9015378249

Thursday, October 3, 2019

Landscape of the Latin America Cancer Screening Market Outlook: Ken Research

The cancer screening effectively focuses to monitor cancer earlier the symptoms appear. This may include the urine tests, blood test, DNA tests and several other relevant test or medical imaging. The advantages of screening in terms of premature detection, cancer prevention and successive treatment must be weighed against any harms. Moreover, the universal screening is also known as the mass screening or populace screening, includes screening everyone, generally within a precise age group. The selective screening recognizes individual who are known to be at sophisticated risk of developing the cancer, namely as individual with a family history of the cancer syndrome.

Additionally, the screening test must be proficient, protective, well-tolerated with the acceptably lower cost of the false positive and false negative conclusions. If the symptoms of cancer are detected, more absolute, and offensive follow-up tests are functioned to reach a treatment. According to the report analysis, ‘Latin America Cancer Screening Market (2018-2023)’ states that in the Latin America Cancer Screening market, there are several key players which presently functioning more positively for leading the fastest market growth and registering the handsome value of market share during the forecasted period more positively while developing the working techniques, increasing the applications, developing the working technologies and delivering the better consumer satisfaction includes Abbott diagnostics, Becton, Dickinson and Company, GE Healthcare, Roche Diagnostics, Hologic Inc., and several others.

Not only has this, the potential players in the Latin America Cancer Screening are implementing the strategies for increasing the value of market share, expanding the business premises, establishing new products, convenient tests, decreasing the price of the procedure and planning for joint venture, partnerships and mergers and acquisitions. Moreover, the large players are scheduling for investing the handsome amount of money for advancing the technologies and spreading the awareness related to this while the government of the economy is also taking initiative in this regards and generating the profitable strategies and policies which further proved to be benefitted for both the consumer and players.

In the recent time, the Latin America cancer screening market is worth at USD 21.24 billion and is reviewed to attain a growth rate of 7.19 % compound annual growth rate (CAGR) leading to a regional revenue of USD 30.06 Bn. The Latin America's growth is much leisurelier compared to several other economies. The economy demands to function absolutely on its socio-economic and political framework to sustenance the untapped growth of the cancer screening market. Furthermore, on the basis of end user, the market is sectored into hospitals, laboratories and independent physicians and clinics. The hospital and laboratory sector will observe a broadminded growth during the forecast period of 2018-2023. The Independent physicians and clinics will effectively observe a vigorous growth rate of 6.28% during the forecast period of 2018-2023.

The increasing pervasiveness of the target disorders, an aging populace, and the existence of the favorable government initiatives for premature disease diagnosis. There is an augmented sustenance from the government in the form of consciousness campaigns and performance-based reimbursements to underwrite towards the growth of the cancer screening market. Therefore, in the near years, it is estimated that the market of cancer screening will increase across the Latin America more positively over the coming years.